Climb Bio, Inc. (CLYM)

NGM – Real Time Price. Currency in USD

13.08

+0.42 (3.32%)

At close: Jun 26, 2026, 4:00 PM EDT

13.07

-0.01 (-0.08%)

After-hours: Jun 26, 2026, 6:47 PM EDT

12.06.2026

Why Is Climb Bio Stock Gaining Friday?

Climb Bio Inc. (NASDAQ:CLYM) on Thursday shared initial data from its ongoing Phase 1b portion of its Phase 1b/2a study of budoprutug for primary immune thrombocytopenia (ITP), an autoimmune disorder where the immune system mistakenly attacks and destroys platelets.

11.06.2026

Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026

Data demonstrate favorable safety and tolerability profile, robust B-cell depletion, and encouraging platelet responses in heavily pretreated patients with primary immune thrombocytopenia Enrollment ongoing in the high dose cohort, with additional data anticipated by year-end 2026 WELLESLEY HILLS, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced initial data from the ongoing Phase 1b portion of its Phase 1b/2a study evaluating budoprutug, an anti-CD19 monoclonal antibody, in adults with primary immune thrombocytopenia (ITP) demonstrating an encouraging safety and tolerability profile, robust B-cell depletion, and meaningful platelet responses in heavily pretreated patients.

05.06.2026

Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development

Company to share additional CLYM116 clinical data and plans for further development at R&D Spotlight in late summer

26.05.2026

Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026

WELLESLEY HILLS, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced upcoming presentations for its CLYM116 and budoprutug programs at the European Renal Association Congress 2026, which will be held in Glasgow, Scotland June 3-6, 2026.

21.05.2026

Climb Bio Teases Key Budoprutug, CLYM116 Readouts at BioConnect

Climb Bio NASDAQ: CLYM outlined its clinical development strategy and upcoming data readouts during a fireside chat at H.C. Wainwright's BioConnect Conference, with management emphasizing two biologic drug programs aimed at immune-mediated diseases, including nephrology and hematology indications.

14.05.2026

Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress

WELLESLEY HILLS, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced an upcoming presentation on its budoprutug program at the European Hematology Association (EHA) 2026 Congress, which will be held in Stockholm, Sweden June 11-14, 2026.

12.05.2026

Climb Bio to Present at Upcoming Investor Conferences

WELLESLEY HILLS, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that members of its executive team will participate in the upcoming conferences detailed below.

Videos

No Data

There is no data to display

Press releases

11.06.2026

Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026

05.06.2026

Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development

Company to share additional CLYM116 clinical data and plans for further development at R&D Spotlight in late summer

07.05.2026

Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates

Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued development CLYM116 modeling and initial Phase 1 safety data to be presented at ERA 2026 with initial Phase 1 PK/PD data expected mid-2026 Budoprutug pMN, ITP, and SLE clinical trials enrolling to plan; anticipate data from all ongoing trials in 2026 Secured $110 million private placement led by top-tier healthcare investors WELLESLEY HILLS, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today reported financial results for the first quarter ended March 31, 2026, and provided business updates.

05.05.2026

Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-Cell Mediated Disease Opportunity, and Upcoming Data Readouts

Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued development Budoprutug pMN, ITP, and SLE clinical trials enrolling to plan; Fast Track Designation received for pMN Initial data from ITP trial anticipated in June; initial data from pMN and SLE trials anticipated Q4 2026 Company to host R&D Spotlight Webcast today, May 5, 2026 WELLESLEY HILLS, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced progress updates for budoprutug, the Company's anti-CD19 monoclonal antibody.

Climb Bio, Inc. (CLYM)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Climb Bio, Inc. (CLYM)

Why Is Climb Bio Stock Gaining Friday?

Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026

Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development

Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026

Climb Bio Teases Key Budoprutug, CLYM116 Readouts at BioConnect

Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress

Climb Bio to Present at Upcoming Investor Conferences

Videos

No Data

Press releases

Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026

Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development

Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates

Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-Cell Mediated Disease Opportunity, and Upcoming Data Readouts

Why Is Climb Bio Stock Gaining Friday?

Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026

Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development

Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026

Climb Bio Teases Key Budoprutug, CLYM116 Readouts at BioConnect

Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress

Climb Bio to Present at Upcoming Investor Conferences

Videos

No Data

Press releases

Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026

Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development

Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates

Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-Cell Mediated Disease Opportunity, and Upcoming Data Readouts

Search stocks

Climb Bio, Inc. (CLYM)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Climb Bio, Inc. (CLYM)

Why Is Climb Bio Stock Gaining Friday?

Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026

Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development

Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026

Climb Bio Teases Key Budoprutug, CLYM116 Readouts at BioConnect

Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress

Climb Bio to Present at Upcoming Investor Conferences

Videos

No Data

Press releases

Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026

Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development

Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates

Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-Cell Mediated Disease Opportunity, and Upcoming Data Readouts

Why Is Climb Bio Stock Gaining Friday?

Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026

Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development

Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026

Climb Bio Teases Key Budoprutug, CLYM116 Readouts at BioConnect

Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress

Climb Bio to Present at Upcoming Investor Conferences

Videos

No Data

Press releases

Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026

Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development

Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates

Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-Cell Mediated Disease Opportunity, and Upcoming Data Readouts